Peptide Immunization against ERG and Immunogenic Mutations to Treat Prostate Cancer
Abstract
Vaccines against prostate cancer are one of the few immunotherapies that have shown success for this cancer. In this project we studied the potential of vaccines targeting the ERG gene and mutations in the tumors. We found that we could generate an anti-tumor T-cell response with peptides against the ERG gene or mutations specific to the tumors. However, we also found that the T-cell response was greatly limited in mice with ERG expressing tumors. We hypothesize that tolerance mechanisms in the cancer bearing mice limit the vaccine responsiveness.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2018
- Accession Number
- AD1060885
Entities
People
- Haydn Kissick
Organizations
- Emory University